8-K - Aspire Biopharma Holdings, Inc. | StockGist

Current Report Details

Event Type

Charter Amendment

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

5.03

. Pursuant to the terms of the Securities Purchase Agreement, on February 2, 2026, the Company filed the Certificate of Designation with the Delaware Secretary

Charter Amendment

9.01

Financial Statements and Exhibits. Exhibit Number Description 3.1 Certificate of Designations of Preferences, Rights and Limitations of the Series A Convertible

Exhibits Only

Exhibits (2)

3.1

EX-3.1

8-K